Abstract

Widespread vaccination against COVID-19 is critical for controlling the pandemic. Despite the development of safe and efficacious vaccinations, low-and lower-middle income countries (LMICs) continue to encounter barriers to care owing to inequitable access and vaccine apprehension. This study aimed to summarize the available data on COVID-19 vaccine acceptance rates and factors associated with acceptance in LMICs. A comprehensive search was performed in PubMed, Scopus, and Web of Science from inception through August 2021. Quality assessments of the included studies were carried out using the eight-item Joanna Briggs Institute Critical Appraisal tool for cross-sectional studies. We performed a meta-analysis to estimate pooled acceptance rates with 95% confidence intervals (CI). A total of 36 studies met the inclusion criteria and were included in the review. A total of 83,867 respondents from 33 countries were studied. Most of the studies were conducted in India (n = 9), Egypt (n = 6), Bangladesh (n = 4), or Nigeria (n = 4). The pooled-effect size of the COVID-19 vaccine acceptance rate was 58.5% (95% CI: 46.9, 69.7, I2 = 100%, 33 studies) and the pooled vaccine hesitancy rate was 38.2% (95% CI: 27.2–49.7, I2 = 100%, 32 studies). In country-specific sub-group analyses, India showed the highest rates of vaccine acceptancy (76.7%, 95% CI: 65.8–84.9%, I2 = 98%), while Egypt showed the lowest rates of vaccine acceptancy (42.6%, 95% CI: 16.6–73.5%, I2 = 98%). Being male and perceiving risk of COVID-19 infection were predictors for willingness to accept the vaccine. Increasing vaccine acceptance rates in the global south should be prioritized to advance global vaccination coverage.

Highlights

  • The highly infectious SARS-CoV-2 virus caused a worldwide outbreak, known as coronavirus disease 2019 (COVID-19), and continues to present threats to nations across the globe

  • We aimed to identify potential factors associated with vaccine acceptance in lower-middle income countries (LMICs)

  • Lazarus et al conducted a survey in 19 countries, but only three were from LMICs [46]

Read more

Summary

Introduction

The highly infectious SARS-CoV-2 virus caused a worldwide outbreak, known as coronavirus disease 2019 (COVID-19), and continues to present threats to nations across the globe. The manifestations of COVID-19 vary from person to person, from asymptomatic or moderate symptoms to a severe course of the illness [1]. The COVID-19 pandemic has taken a significant toll on the health of the globe in terms of incidence, mortality, mental health, and quality of life. As of 4 February 2022, the world crossed the threshold of 300 million COVID-19 cases and 5.7 million deaths [2]. There is currently no therapeutic for SARS-CoV-2 infection that has been proved to be consistently effective in controlled trials. The worldwide immunization against SARS-CoV-2 offers the possibility for a breakthrough in the battle against the severe effects of this emergent virus [1]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call